Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases.

Tang C, Luo D, Yang H, Wang Q, Zhang R, Liu G, Zhou X.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):386-94. doi: 10.1097/PAI.0b013e31827da3f9.

PMID:
23343958
2.

Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.

Cancer. 2005 Apr 15;103(8):1676-84.

3.

Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis.

Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y.

Br J Cancer. 2006 Nov 20;95(10):1371-8. Epub 2006 Oct 31.

4.

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.

Suzuki M, Iizasa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H, Suzuki H.

Invasion Metastasis. 1998-1999;18(3):134-41.

PMID:
10474026
5.

[Expression and its clinical significance of SHP2 in non-small cell lung cancer].

Tang C, Zhou X, Yang H, Wang Q, Zhang R.

Zhongguo Fei Ai Za Zhi. 2010 Feb;13(2):98-101. doi: 10.3779/j.issn.1009-3419.2010.02.03. Chinese.

6.

Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.

Jobim FC, Xavier NL, Uchoa DM, Cruz DB, Saciloto M, Chemello N, Schwartsmann G.

Braz J Med Biol Res. 2009 Oct;42(10):979-87. Epub 2009 Sep 4.

7.

Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).

Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O.

J Thorac Oncol. 2010 Sep;5(9):1354-60. doi: 10.1097/JTO.0b013e3181e77a78.

8.

Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma.

Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y.

Anticancer Res. 2006 Sep-Oct;26(5A):3579-83.

9.

[Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis].

Wang L, Zhang LH, Li YL, Li YL, Liu Z.

Zhonghua Yi Xue Za Zhi. 2003 May 10;83(9):782-6. Chinese.

PMID:
12899759
10.

Correlation between matrix metalloproteinase-9 and vascular endothelial growth factor expression in lung adenocarcinoma.

Wen YL, Li L.

Genet Mol Res. 2015 Dec 29;14(4):19342-8. doi: 10.4238/2015.December.29.44.

11.

Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM.

J Clin Oncol. 2012 Apr 1;30(10):1129-36. doi: 10.1200/JCO.2011.37.4231. Epub 2012 Feb 21.

12.

Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.

Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H.

Anticancer Res. 2002 Nov-Dec;22(6C):3977-84.

PMID:
12553021
13.

Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer.

Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, Hao T, Zhang X, Li M, Zhang F, Li Q, Lu B, Qiao L.

Tumour Biol. 2010 Dec;31(6):549-58. doi: 10.1007/s13277-010-0068-y. Epub 2010 Jun 19.

PMID:
20563765
14.

Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.

Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.

Cancer Lett. 2006 May 8;236(1):125-32. Epub 2005 Jun 27. Erratum in: Cancer Lett. 2007 Mar 18;247(2):359.

PMID:
15982804
16.

Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.

Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.

PMID:
10810441
17.
18.

Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.

Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y.

Lung Cancer. 2006 Jul;53(1):91-6. Epub 2006 May 11.

PMID:
16697074
19.

[Expression and significance of matrix metalloproteinase and tissue inhibitor of metalloproteinase in nasal cavity squamous cell carcinoma].

Zheng Y, Ding J, Wang CL, Jiao SS, Qu LM, Bahargul, Bao H, Chen X.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Apr;46(4):299-302. Chinese.

PMID:
21624249
20.

[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].

Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY.

Ai Zheng. 2007 Jul;26(7):785-9. Chinese.

PMID:
17626761

Supplemental Content

Support Center